1. Unveiling the mechanism of action of nature-inspired anti-cancer compounds using a multi-omics approach
    Nelson C. Soares et al, 2022, Journal of Proteomics CrossRef
  2. Crosstalk between Ca2+ Signaling and Cancer Stemness: The Link to Cisplatin Resistance
    Sana Kouba et al, 2022, IJMS CrossRef
  3. Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings
    Giovanni Tossetta, 2022, IJMS CrossRef
  4. Role of RAS signaling in ovarian cancer
    Lubna Therachiyil et al, 2022, F1000Res CrossRef
  5. Immunogenic cell death-related gene landscape predicts the overall survival and immune infiltration status of ovarian cancer
    Wenwen Zhang et al, 2022, Front. Genet. CrossRef
  6. A trans-Pt(ii) hedgehog pathway inhibitor complex with cytotoxicity towards breast cancer stem cells and triple negative breast cancer cells
    Aisling L. Ryan et al, 2022, Dalton Trans. CrossRef
  7. New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic
    Xiaojing Yang et al, 2022, Front. Oncol. CrossRef
  8. Therapy-Induced Stromal Senescence Promoting Aggressiveness of Prostate and Ovarian Cancer
    Elisa Pardella et al, 2022, Cells CrossRef
  9. Targeting the NRF2/KEAP1 pathway in cervical and endometrial cancers
    Giovanni Tossetta et al, 2023, European Journal of Pharmacology CrossRef
  10. Identification of EMP1 as a critical gene for cisplatin resistance in ovarian cancer by using integrated bioinformatics analysis
    Qingsong Zeng et al, 2023, Cancer Medicine CrossRef
  11. Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance
    Ebrahim H. Maleki et al, 2023, Genes & Diseases CrossRef
  12. Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug–Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines
    Marie-Christin Barth et al, 2023, IJMS CrossRef
  13. Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
    Shicheng Yang et al, 2023, Front. Oncol. CrossRef
  14. Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma
    Min Yin et al, 2023, BMC Women's Health CrossRef
  15. A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis
    Philipp König et al, 2023, Cancer Chemother Pharmacol CrossRef
  16. Aberrant epigenetic regulation of FZD3 by TET2 is involved in ovarian cancer cell resistance to cisplatin
    Li Zhu et al, 2023, Journal of Chemotherapy CrossRef
  17. Mechanisms of autophagy and endoplasmic reticulum stress in the reversal of platinum resistance of epithelial ovarian cancer cells by naringin
    Jun Zhu et al, 2023, Mol Biol Rep CrossRef
  18. Targeting the stimulator of interferon genes (STING) in breast cancer
    Ma Ying-Rui et al, 2023, Front. Pharmacol. CrossRef
  19. Scutellaria baicalensis Georgi and Their Natural Flavonoid Compounds in the Treatment of Ovarian Cancer: A Review
    Jiaying Cai et al, 2023, Molecules CrossRef
  20. Potentiation of Cisplatin Cytotoxicity in Resistant Ovarian Cancer SKOV3/Cisplatin Cells by Quercetin Pre-Treatment
    Aseel Ali Hasan et al, 2023, IJMS CrossRef
  21. Single-cell RNA sequencing reveals a pro-metastatic subpopulation and the driver transcription factor NFE2L1 in ovarian cancer cells
    Junseong Park et al, 2023, Genes Genom CrossRef
  22. Chemotherapy‐induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer
    Gerrit Hugendieck et al, 2023, J of Extracellular Vesicle CrossRef
  23. Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers
    Tetiana Korzun et al, 2023, Small CrossRef
  24. Glucose-6-phosphate dehydrogenase: a therapeutic target for ovarian cancer
    Chenxi Wang et al, 2023, Expert Opinion on Therapeutic Targets CrossRef